Vinorelbine ditartrate

Research use only, not for human use.

Vinorelbine (KW-2307) is a vinca alkaloid chemotherapy agent that inhibits cancer cell mitosis through interaction with tubulin.

Vinorelbine (KW-2307) is a vinca alkaloid chemotherapy agent that inhibits cancer cell mitosis through interaction with tubulin, inhibits HeLa cell proliferation with IC50 of 1.25 nM; induces Hela mitotic block at the metaphase/anaphase transition with IC50 of 3.8 nM, blocks cells exhibited aberrant spindles, consistent with induction of block by suppression of microtubule dynamics.Chemotherapeutic Agents Approved(In Vitro):Vinorelbine (0.5-5 nM) inhibits cell proliferation by 50% (IC50) at concentrations of 1.25 nM. At concentration of 8 nM vinorelbine, no cells are in anaphase. Vinorelbine time-dependently induces the p53 and p21WAFI/CIP1 expression in androgen-dependent (AD) and- independent (AI) prostate cancer cell lines. Vinorelbine stimulates reporter genes in a concentration-dependent manner.(In Vivo):After vinorelbine treatment, the first neutropenicepisode occurred after the first (4 dogs), second (1), or sixth(1) vinorelbine treatment in the dogs. Vinorelbine is tolerated at a weekly interval in tumor-bearing cats, with an MTD of 11.5 mg/m2.

——

——

KW-2307 | Nor-5'-anhydrovinblastine ditartrate

Cytoskeleton/Cell Adhesion Molecules

Microtubule/Tubulin

Tubulin

Cancer

Chemotherapeutic

125317-39-7

1079.106

C53H66N4O20

>98% (HPLC)

DMSO: ≥ 46 mg/mL

CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC.C(C(C(=O)O)O)(C(=O)O)O.C(C(C(=O)O)O)(C(=O)O)O

Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2β,3β,4β,5α,12R,19α)-, (2R,3R)-2,3-dih

(-20℃)

With Ice Pack

≥ 2 years